水痘帯状疱疹感染症:治療薬開発のグローバルパイプライン動向(2014年下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5265IDB)
◆英語タイトル:Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5265IDB
◆発行日:2014年7月31日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[水痘帯状疱疹感染症:治療薬開発のグローバルパイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2014’, provides an overview of the Varicella Zoster (HHV-3) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Varicella Zoster (HHV-3) Infections Overview 7
Therapeutics Development 8
Pipeline Products for Varicella Zoster (HHV-3) Infections – Overview 8
Pipeline Products for Varicella Zoster (HHV-3) Infections – Comparative Analysis 9
Varicella Zoster (HHV-3) Infections – Therapeutics under Development by Companies 10
Varicella Zoster (HHV-3) Infections – Therapeutics under Investigation by Universities/Institutes 12
Varicella Zoster (HHV-3) Infections – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Varicella Zoster (HHV-3) Infections – Products under Development by Companies 15
Varicella Zoster (HHV-3) Infections – Products under Investigation by Universities/Institutes 16
Varicella Zoster (HHV-3) Infections – Companies Involved in Therapeutics Development 17
Novavax, Inc. 17
SK Chemicals Co., Ltd. 18
Green Cross Corporation 19
Beijing Tiantan Biological Products Co., Ltd. 20
Epiphany Biosciences, Inc. 21
China National Pharmaceutical Group Corporation 22
Chongqing Zhifei Biological Products Co., Ltd. 23
Varicella Zoster (HHV-3) Infections – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 31
Drug Profiles 33
valomaciclovir stearate – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Vaccine for Varicella Zoster Infections – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
measles + mumps + rubella + varicella vaccine – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MG-1111 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
measles + mumps + rubella + varicella vaccine – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Varicella Vaccine – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Varicella Zoster Virus Vaccine – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit Cyclophilins – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Sattabacin – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HHV-3 vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Varicella Zoster (HHV-3) Infections – Recent Pipeline Updates 45
Varicella Zoster (HHV-3) Infections – Dormant Projects 46
Varicella Zoster (HHV-3) Infections – Discontinued Products 47
Varicella Zoster (HHV-3) Infections – Product Development Milestones 48
Featured News & Press Releases 48
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 48
Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 48
Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 49
May 13, 2004: ProQuad, Merck’s Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2014 8
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Varicella Zoster (HHV-3) Infections - Pipeline by Novavax, Inc., H2 2014 17
Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H2 2014 18
Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H2 2014 19
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 20
Varicella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H2 2014 21
Varicella Zoster (HHV-3) Infections - Pipeline by China National Pharmaceutical Group Corporation, H2 2014 22
Varicella Zoster (HHV-3) Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Assessment by Combination Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Varicella Zoster (HHV-3) Infections Therapeutics - Recent Pipeline Updates, H2 2014 45
Varicella Zoster (HHV-3) Infections - Dormant Projects, H2 2014 46
Varicella Zoster (HHV-3) Infections - Discontinued Products, H2 2014 47

List of Figures
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2014 8
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Top 10 Target, H2 2014 26
Number of Products by Stage and Top 10 Target, H2 2014 27
Number of Products by Top 10 Mechanism of Action, H2 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 29
Number of Products by Top 10 Molecule Type, H2 2014 31
Number of Products by Stage and Top 10 Molecule Type, H2 2014 32

*** 掲載企業 ***

Novavax, Inc.
SK Chemicals Co., Ltd.
Green Cross Corporation
Beijing Tiantan Biological Products Co., Ltd.
Epiphany Biosciences, Inc.
China National Pharmaceutical Group Corporation
Chongqing Zhifei Biological Products Co., Ltd.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5265IDB )"水痘帯状疱疹感染症:治療薬開発のグローバルパイプライン動向(2014年下半期)" (英文:Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。